Schedule 13G ownership disclosure

ALNYLAM PHARMACEUTICALS INC COM

Common Stock · CUSIP: 02043Q107

Event date: 2025-03-31

Filing-level shares
13,056,605
Percent of class
10.03%
  • The Vanguard Group

    Shares: 13,056,605 · Class: 10.03%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0000932471-25-000378
Form type
SCHEDULE 13G/A
Filer
ALNYLAM PHARMACEUTICALS, INC.
CIK
CIK 1178670
Filed
Apr 07, 2025
Reporting period
Mar 31, 2025
Description
Schedule 13G beneficial ownership

Explore SEC Filings Hub